Barclays Initiates Biogen Idec At Overweight - Biogen (NASDAQ:BIIB)

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Analysts at Barclays initiated coverage on shares of Biogen Idec Inc. (NASDAQ: BIIB) with a Overweight rating. The target price for Biogen Idec is set to $425. Biogen Idec shares have surged 23.11% over the past 52 weeks, while the S&P 500 index has gained 9.94% in the same period.Biogen Idec's shares fell 1.54% to close at $336.74 yesterday.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!